DexCom (DXCM) Stock Price, News & Analysis

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year target prices for DexCom's shares. Their DXCM share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $141.40 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $124.09 at the start of the year. Since then, DXCM stock has increased by 8.2% and is now trading at $134.30.
View the best growth stocks for 2024 here.

DexCom saw a decline in short interest in March. As of March 31st, there was short interest totaling 14,570,000 shares, a decline of 8.2% from the March 15th total of 15,870,000 shares. Based on an average daily volume of 3,090,000 shares, the days-to-cover ratio is currently 4.7 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast.

DexCom will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Thursday, February, 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. The medical device company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. The firm's revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.34 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Internet of Things Thematic ETF (SNSR), Subversive Mental Health ETF (SANE), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), Harbor Health Care ETF (MEDI), iShares U.S. Medical Devices ETF (IHI) and Global X Telemedicine & Digital Health ETF (EDOC).

DexCom's stock split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vaughan Nelson Investment Management L.P. (0.37%), Allspring Global Investments Holdings LLC (0.33%), Congress Asset Management Co. MA (0.29%), Los Angeles Capital Management LLC (0.09%), Congress Wealth Management LLC DE (0.04%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.